Clinical efficacy of controlled-release oxycodone 20 mg administered on a 12-h dosing schedule on the management of postoperative pain after breast surgery for cancer

SUMMARY Objective: To assess clinical efficacy of controlled-release oxycodone (CRO) 20 mg on a 12-h dosing schedule in this prospective, randomised, placebo-controlled, double-blinded study of 40 ASA physical status I-III women undergoing breast surgery for cancer. Research design and methods: Gene...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2004-01, Vol.20 (2), p.199-202
Main Authors: Kampe, Sandra, Warm, Mathias, Kaufmann, Jost, Hundegger, Stephanie, Mellinghoff, Hermann, Kiencke, Peter
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Analgesics, Opioid - administration & dosage
Analgesics, Opioid - pharmacology
Area Under Curve
Breast Neoplasms - surgery
Breast surgery
Controlled-release oxycodone
Delayed-Action Preparations
Double-Blind Method
Drug Administration Schedule
Efficacy
Female
Humans
Middle Aged
Oxycodone - administration & dosage
Oxycodone - pharmacology
Pain, Postoperative - drug therapy
Postoperative analgesia
Prospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SUMMARY Objective: To assess clinical efficacy of controlled-release oxycodone (CRO) 20 mg on a 12-h dosing schedule in this prospective, randomised, placebo-controlled, double-blinded study of 40 ASA physical status I-III women undergoing breast surgery for cancer. Research design and methods: General anaesthesia using remifentanil and propofol was performed for surgery. Both groups received premedication with oral midazolam 7.5 mg 1 h before surgery. In the controlled-release oxycodone group, one tablet of 20 mg CRO was administered with the premedication, and 12 h after the premedication another 20 mg CRO. In the placebo (PL) group, a placebo tablet was administered with the premedication, and 12 h later another placebo tablet. All patients had access to opioid rescue medication via an IV patient-controlled analgesia (PCA) device. Main outcome measures: Area under the curve (AUC), based on IV opioid rescue consumption over 24 h postoperatively. Results: The AUC for IV PCA opioid consumption was significantly lower in the CRO group than in the PL group (p = 0.01). The CRO group required less IV opioid loading dose (p 
ISSN:0300-7995
1473-4877
DOI:10.1185/030079903125002874